RAPPRapport Therapeutics, Inc.
$30.68+16% 1Y
$30.68
$24.3752 weeks$52.44
The financials
Rapport Therapeutics, Inc. by the numbers
Rapport Therapeutics, Inc. (RAPP) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $57M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | n/a |
| Operating income | −$61M | −$29M | n/a |
| Net income | −$57M | −$27M | n/a |
| Diluted EPS | −$1.19 | −$0.75 | n/a |
Biotechnology
The closest names by size in the same industry